Hypothesis

Aging stem cells lose chromatin accessibility at stemness regulatory elements and gain accessibility at myeloid/ progenitor loci not merely because of passive DNA methylation changes but due to a progressive decline in the activity of the nucleosome‑remodeling CHD4 subunit of the NuRD complex. Reduced CHD4 leads to aberrant nucleosome positioning that occludes binding sites for pro‑quiescence factors (e.g., MEF2C) in hematopoietic and neural stem cells while simultaneously exposing cryptic enhancer regions enriched for CEBP motifs, thereby driving myeloid priming and niche‑adhesion dysregulation. This mechanism predicts that restoring CHD4 activity in aged stem cells will re‑establish youthful accessibility patterns and functional regenerative capacity, whereas CHD4 loss in young cells will recapitulate the aged ATAC‑seq signature.

Testable Predictions

1. Chromatin phenotype – Conditional CHD4 knockout in young HSCs or NSCs will reproduce the aged ATAC‑seq profile: loss of accessibility at stemness enhancers (e.g., GATA2, TAL1) and MEF2C sites, and gain of accessibility at CEBP‑bound myeloid progenitors and niche‑adhesion genes.
2. Rescue experiment – Forced expression of CHD4 (via inducible lentiviral vector) in aged HSCs transplanted into young recipients or in aged hippocampal NSCs will restore accessibility at stemness and quiescence loci, reduce CEBP‑driven myeloid priming, and normalize niche‑adhesion/migration gene accessibility.
3. Functional correlate – CHD4‑rescued aged stem cells will show improved competitive repopulation (HSC) or increased neurogenesis and improved migration (NSC) comparable to young controls, while CHD4‑deficient young cells will display reduced repopulation and neurogenesis.
4. Mechanistic link – CUT&RUN for CHD4 in young versus aged stem cells will reveal decreased CHD4 occupancy at the same loci that lose accessibility in ATAC‑seq, and nucleosome‑mapping (MNase‑seq) will show increased nucleosome density at stemness enhancers and decreased density at CEBP sites in aged cells.
5. Pharmacological test – Small‑molecule activators of the NuRD complex (e.g., HDAC inhibitors that promote CHD4 recruitment) will partially rescue the aged accessibility pattern, whereas NuRD inhibition will exacerbate it even in young cells.

Falsifiability

If CHD4 manipulation does not alter the ATAC‑seq accessibility landscape as predicted, or if accessibility changes occur without corresponding changes in CHD4 occupancy/nucleosome positioning, the hypothesis would be refuted. Likewise, if restoring CHD4 fails to improve functional outcomes despite chromatin normalization, the causal link between CHD4‑driven accessibility and stem cell rejuvenation would be weakened.

Broader Impact

Demonstrating a cell‑intrinsic remodeling defect as a driver of epigenetic erosion would shift focus from purely signaling‑based rejuvenation strategies to targeted chromatin‑engineering approaches, potentially applicable across hematopoietic, neural, and other stem cell systems undergoing age‑related functional decline.